GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

zoliflodacin   Click here for help

GtoPdb Ligand ID: 10875

Synonyms: AZD-0914 | AZD0914 | EXT-0914 | EXT0914 | Nuzolvence®
Approved drug PDB Ligand
zoliflodacin is an approved drug
Compound class: Synthetic organic
Comment: Zoliflodacin is a first-in-class spiropyrimidinetrione antibacterial compound that has been developed for the treatment of gonorrhea [2-3]. The compound inhibits bacterial type II topoisomerases with a unique mode of action [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

zoliflodacin is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 143.31
Molecular weight 487.15
XLogP 1.37
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@H]1O[C@@H](C)[C@H]2N(C1)c1c(CC32C(=O)NC(=O)NC3=O)cc2c(c1F)onc2N1[C@@H](C)COC1=O
Isomeric SMILES C[C@H]1O[C@@H](C)[C@H]2N(C1)c1c(CC32C(=O)NC(=O)NC3=O)cc2c(c1F)onc2N1[C@@H](C)COC1=O
InChI InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1
InChI Key ZSWMIFNWDQEXDT-ZESJGQACSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Zoliflodacin was developed as a single-dose oral treatment for uncomplicated gonorrhoea, through a public-private partnership between the Global Antibiotic Research and Development Partnership (GARDP) and Innoviva Specialty Therapeutics. The Phase 2 formulation was found to be unsuitable for further development and an alternative formulation (granules for oral suspension) was used in subsequent studies [4-5].
First approval was granted by the FDA in December 2025, to treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae. Together with gepotidacin (granted FDA approval the day before zoliflodacin), it is the first new antibacterial treatment for gonorrhea in 30 years.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Inhibits bacterial DNA gyrase and DNA topoisomerase 4 [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03959527 Zoliflodacin in Uncomplicated Gonorrhoea Phase 3 Interventional Global Antibiotics Research and Development Partnership Zoliflodacin demonstrated non-inferiority for the treatment of uncomplicated urogenital gonorrhoea and a similar safety profile compared to ceftriaxone plus azithromycin. 5